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Abstract
Non-covalent interactions involving π-π stacking play an essential role in self-assembly
and molecular recognition processes such as protein folding and DNA/RNA-protein selective
recognition. The knowledge gained from these studies could provide insight into possible site
recognition complexes, inhibiting or mimicking protein-protein or protein-DNA interactions.
Based on molecular modeling as well as HOMO and LUMO energies, several
chromophores were selected with a variety of ∆ε values (∆ε= |εHOMO,NAcTrp – εLUMO,chromophores|),
high and low, to establish a correlating trend with the modeling and experimental data. The
corresponding Pt(dien) compounds were synthesized and their ability to stack to N-acetyl
tryptophan was evaluated by fluorescence quench experiments. Attaching a strong electron
donating/withdrawing group or extending the π system of pyridine or thiazole by means of a
benzene ring (quinoline and benzothiazole) was found to enhance the π-π interaction with Nacetyl tryptophan.
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Chapter 1 Introduction
1.1. π stacking
Non-covalent interactions involving π-π stacking are pivotal in biological process and can range
from reasonably small molecules to large biological systems.[1-5] They play an essential role in
self-assembly and molecular recognition processes such as protein folding and DNA/RNAprotein selective recognition.[6] These π-π interactions are non-covalent intermolecular forces
just as important as hydrogen bonding.[7] The term “π-π interaction” is often used
indiscriminately, where it is mistakenly expected that aromatic rings will interact through π-π
parallel stacking interaction, face-to-face. Aromatic rings may interact through several
distinguishable arrangements: stacked, an edge or point-to-face, or T-shaped conformation
(Figure 1.1).[7]

Figure 1.1. Principal orientations of aromatic-aromatic interactions[7]
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Both the face-to-face and T-shaped stacking arrangements are limiting forms in aromatic
interactions.[7] The electrostatic and Van der Waals interactions [dipole-dipole (electrostatic)
interaction, dipole-induced-dipole interaction, and induced-dipole induced dipole (London)
dispersion interactions] are the intermolecular forces for the stabilization of π-π interactions
between closed shell molecules.[3] Dipole-dipole (electrostatic) interactions are interactions
between different permanent and static molecular charge distributions. Dipole-induced-dipole
interactions are interactions between the static molecular charge distribution of group A with a
proximity induced change in charge distribution of group B. Induced-dipole-induced-dipole
(London) dispersion interactions are where an instantaneous dipole moment from a fluctuation
electron cloud polarizes a neighboring molecule and induces in it also an instantaneous dipole.[7]
(Figure 1.2)

Figure 1.2. Pictorial representation of the electrostatic interactions.[7]
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These electrostatic and Van der Waals interactions are essentially attractive forces but are
dependent on distance, with their potentials falling off rapidly with distance by 1/r6. [7] At very
short distances repulsion becomes the main interacting force due to the overlap of the filled
electron clouds of the electron shells of the molecules involved in the interaction. A prototypical
model for π-π interactions in aromatic systems is benzene. [8-10] With a benzene-benzene
interaction the T-shaped motif is found to be the most favorable orientation due to the repulsion
of the negatively charged out of plane π electrons. (Figure 1.3)

Figure 1.3. π-π repulsion in benzene-benzene interaction if in face-to-face alignment.[7]

[5]The point- or edge-to-face, edge-on, or T-shaped orientation can be seen as the motif for arene
interaction in many protein structures.[11-14] In π systems that are extended or polarized,
through substituents or heteroatoms, the conclusions drawn from benzene are considerably
changed. The addition of substituents or heteroatoms disturbs the uniform charge distribution,
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which results in partial atomic charges and a permanent dipole.[3, 5] This permanent dipole
induces dipole-dipole and dipole induced dipole interactions as well as affect atom-atom and out
of plane atom π-electron interactions (Figure 1.3). [3, 5] Having a nitrogen heteroatom (electronwithdrawing) within the ring decreases the π-electron density in the ring, resulting in a decrease
in the π-electron repulsion and an increase in stability of the face-to-face π stacking moiety.
(Figure 1.4)

Figure 1.4. Decrease in π-electron density for aromatic rings containing a nitrogen heteroatom
within the ring.[7]

Therefore, aromatic moieties such as pyridine, bypyridines, and other aromatic nitrogen
heterocycles should produce more stable π stacked complexes.
1.2. π-π stacking Interactions in Biological Processes
1.2.a DNA mismatch repair
As mentioned previously, non-covalent interactions involving π-π stacking play an
essential role in self-assembly and molecular recognition processes such as protein folding and
DNA/RNA-protein selective recognition.[6] MutS, a mismatch DNA repair protein, is an
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example of DNA-protein selective recognition.[15, 16] DNA mismatch repair (MMR) corrects
mispaired or unpaired bases caused by DNA polymerase, increasing the overall reliability of
DNA replication up to a 1,000-fold.[15, 17] Cells that contain mutations in MMR genes are
characterized by the elevated rates of spontaneous mutation and instability of microsatellite
repeats.[15] MMR genes can be deactivated by mutation or epigenetic process but predisposes
people to nonpolyposis colorectal cancer (HNPCC) and random tumors.[18] Escherichia coli
contains three MMR proteins, MutS, MutL and MutH. These MMR proteins set off a strand
specific mismatch repair process that takes advantage of the briefly unmethylated state of the
daughter strand, when newly synthesized. [15] The MMR protein MutS specifically recognizes
mispaired or unpaired bases, up to four, and with the aid of MutL, will activate the endonuclease
MutH initiating the repair process. Homologues of E. coli MutS have been found in nearly all
organisms. [16] The bulk of the MutS proteins are related to the proteins that are involved with
MMR, preventing homologous DNA recombination between heterologous sequences and
mediating in cell death. [16, 19] The mechanism of MutS recognition of large range of
mismatches embedded in a random DNA sequence remained unclear until Obmolova et al.
obtained crystal structures of Thermus aquaticus (TAQ) MutS. TAQ MutS is a thermostable
homologue of E. coli. TAQ MutS protein has been co-crystallized with a 21-bp hetero-duplex
containing an unpaired thymidine (T).[7] (Figure 1.5)

15

Figure 1.5. Unpaired T in the MutS co-crystal partially stacked in the DNA duplex[20]
The unpaired base is displaced towards the minor groove by 3Å and tilts toward the 5’ base
pair.[20] The conformation is stabilized by the stacking of a phenylalanine of the MutS. (Figure
1.6)

Figure 1.6. Stacking of Phe 39 of the MutS to the unpaired T of the DNA.[20]
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The phenylalanine approaches the DNA from the minor groove side and recognizes the unpaired
or mismatched thymidine. It stacks onto the unpaired thymidine in order to initiate the process of
repair.
1.2.b

π-π stacking interactions in stabilization of complexes
DNA enzymes are a class of catalysts that are composed of single stranded DNA that

catalyze a variety of chemical reactions such as cleavage and formation of phosphoester bonds,
porphyrin metallation, and oxidative cleavage of DNA.[21] The 10-23 DNA enzyme catalyses
the sequence-specific cleavage of RNA[22] and, more specifically, the phosphoester bond
between an unpaired purine and paired pyrimidine residue within the RNA substrate. In the case
of structural stabilization, π-π interactions play an important role in the 82-nucleotide RNA-DNA
complex formed by the 10-23 DNA enzyme.[23] 10-23 DNA is composed of a 15-nucleotide
catalytic core, which is flanked by two substrate recognition domains. When the 10-23 DNA was
crystallized with a RNA substrate it formed a complex containing five double-helical regions,
two strands of DNA and two strands of RNA.[23] For each RNA substrate two DNA enzymes
were bound by six nucleotides at the 5’ end of the RNA binding to one DNA enzyme and seven
nucleotides at the 3’ end binding to the second DNA enzyme. (Figure 1.7)
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Figure 1.7. Three dimensional structure of the 82-nucleotide RNA-DNA complex.[23]

Only three of the five helices are unique due to symmetry of the complex. Stems 1 and 2 take on
an A-form geometry and stem 3, bridging stem 1 and 2, takes on a B-form. Each end of stem 3
interacts with the DNA through the stacking of threonine-adenine base pair to guanine-cytosine
base pair. As a whole, the three dimensional shape of the RNA-DNA complex is stabilized by
extensive base stacking and pairing of the nucleotides; all 82 of the nucleotide bases of the
complex are involved in stacking intra- or intermolecularly. (Figure 1.8)[23]
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Figure 1.8. View of complex perpendicular to the principal axis, showing stacking
interactions.[23]

1.2.c Interfering with p53-MDM2 interaction
The protein p53 has been referred to as the “guardian of the genome”. P53 works as a
transcriptase factor that regulates the cell cycle and functions as a tumor suppressor. [24, 25] P53
is upregulated when the cell undergoes any kind of stress. Accumulation of p53 in the cell can
trigger cell growth arrest, apoptosis, or senescence.[23] Another protein MDM2 is a negative
regulator for p53. When bound to p53 MDM2 inactivates and promotes degradation.[26] The
amount of the p53 and MDM2 expressed in the cell are correlated. There have been several
strategies to activate the p53 pathway and utilize it as an anticancer target.[27] One strategy is to
disrupt the p53-MDM2 interaction, releasing p53 from negative control.[28] One compound
synthesized, called RITA, binds to p53 and disrupts the interaction between MDM2 and p53,
releasing p53 to be able to accumulate in the cell nucleus and induce apoptosis.[24] The
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mechanism in which it inhibits p53-MDM2 binding is not fully understood. Another class of
compounds called nutlins interferes with the binding of p53 and MDM2 by binding to the
MDM2 hydrophobic cavity and mimicking the interaction of the three critical p53 amino acids
(Phenylalanine, Tryptophan, and Leucine).[25-27] Nutlins have the capability to penetrate cell
membranes, activate the p53 pathway, and inhibit cell growth. The approach in this research was
to target the amino acids tryptophan and phenylalanine on the N-terminal sequence of p53 and
use platinum based molecules designed to п stack tryptophan and or phenylalanine to block the
interaction between p53 and MDM2. (Figure 1.9)

Figure 1.9. Crystal structure of p53 (green)/MDM2 (yellow and white) binding pocket. Three
amino acids of p53 shown inside binding pocket, leucine, tryptophan and phenylalanine; which
are essential for the binding of MDM2.[29]

1.2.d Disruption of HIV-I zinc finger NCp7 function
Zinc fingers are one of the most abundant class of metalloproteins in the human
proteome. Zinc fingers typically consist of a definite amount of amino acid residues, 30 to 40,
with suitable Zn-binding sites[30]. The zinc ion (Zn2+) is the key component of the system and
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will bind to the residues in a tetrahedral arraignment; which is essential for its function. Release
or substitution of the zinc ion will result in a loss of the zinc fingers function.
It was found that Zinc fingers that are used as spacers for DNA interaction are involved
in the interaction with RNA[30]. One of the interactions between the Zinc finger and DNA/RNA
is by π-stacking with a tryptophan residue of the zinc finger and an adenine of DNA/RNA. This
π-stacking interaction with aromatic residues of the zinc finger, tryptophan and phenylalanine,
and nucleobases has been seen for the HIV Nucleocapsid 7 protein (NCp7)[31]. (Figure 1.10)

Figure 1.10. Sequence of NCp7 showing coordinating residues in red. [32]

It has been established that the π-stacking interactions play an important role in selectivity and
recognition between the NCp7 and its substrate, the Ψ site in the viral RNA. Studies using
models of the Ψ site in the viral RNA showed important π-stacking interaction between aromatic
nucleobases with the phenylalanine (F16) and the tryptophan (W37) in the zinc finger of
NCp7[31, 33, 34]. Platinum-aromatic chromophores complexes could be used for molecular
recognition of NCp7 by means of π-stacking with W37 or F16; resulting in a displacement of the
zinc ion, loss of structure and loss of function. NCp7 is a C3H zinc finger and the molecular
recognition by C3H zinc fingers differ from the most common zinc fingers found in the human
body[35], C2H2 and C4, providing a possible specific way to target for NCp7[36].
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1.3. Nucleobase Modification
There are several amino acids in the human body that contain aromatic groups and are
capable of π-π stacking interactions. (Figure 1.11)

Figure 1.11. Amino acids capable of π-π stacking interactions
These amino acids play an important role in DNA/RNA-protein recognition; generally stacking
with cytosine and guanine, (Figure 1.12). [6, 23, 37, 38]

Figure 1.12. Nucleobases adenine (A), guanine (G), thymine (T), and cytosine (C).
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Methylation of purine or pyrimidine based nucleic acids will enhance the π-π stacking
interactions when stacking with tryptophan.[39] This enhancement is due to the lowering of the
energy of the lowest unoccupied molecular orbital (LUMO) of the π acceptor, bringing it close in
energy to the highest occupied molecular orbital (HOMO) of the π donor. The decrease in the
energy gap (ΔE) between the LUMO of the π-acceptor and the HOMO of the π-donor, improves
the acceptor properties toward the π-donor. (Figure 1.13)

Figure 1.13. Protonation, alkylation or coordination of a metal ion such as Pd(II) or Pt(II) to a
nucleobase strengthens the interaction by lowering the energy of the lowest unoccupied
molecular orbital of the modified nucleobases (LUMO) and improving overlap with the highest
occupies molecular orbital (HOMO) in N-acetyl tryptophan.[40]

A metal which is coordinated with the nucleic acid base will further enhance the π stacking
capability by further decreasing the gap between the HOMO of the π-donor (tryptophan) and the
LUMO of the π-acceptor (metallated nucleobase).[41] Two metals that are notably used in
increasing the π-π stacking interactions are Pt(II) and Pd(II). [42, 43]

Coordination of a

nucleobase by either Pt(II) or Pd(II) will produce a complex with a higher net charge (+2),
compared to just methylation (+1) of the nucleobase; producing a larger decrease in the energy
of LUMO by 7-8 eV (electron volts) .[41] Comparing Pt(II) to Pd(II), Pt(II) metallated
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nucleobases produced a smaller energy gap between the HOMO of the π-donor (tryptophan) and
the LUMO of the π-acceptor (metallated nucleobase). This indicates that coordinating a Pt(II)
metal to the nucleobase will enhance the π-stacking interaction versus coordinating a Pd(II)
metal. (Figure 1.14)

Figure 1.14. HOMO/LUMO energies for nucleobases, methylated nucleobases and metal
coordinated nucleobases. Dash line is the HOMO of N-AcTrp. [Pd(dien)(1-MethylCytosiene)]2+
(1);
[Pt(dien)(1-MethylCytosine)]2+ (2); [Pd(dien)(9-EthylGuanine)]2+ (3); [Pt(dien)(9EthylGuanine)]2+ (4).

These results suggest a novel structural design for metal coordinated complexes that are capable
of recognition and probing of DNA- or RNA-protein interactions and protein-protein interactions
involving tryptophan.
Previous work done by Anzellotti et al. suggested a nucleobase has enhanced capabilities
to п stack with tryptophan when attached a platinum ion (Pt+2).[44] This enhancement is a result
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of lowering the energy of the LUMO in the platinated nucleobase (п acceptor), bringing it closer
in energy to the HOMO of tryptophan (п donor).[44] (Figure 1.15)

Figure 1.15. Platination, Pt(II), of a nucleobase enhances the interaction by lowering the energy
of the LUMO of the nucleobase and improving the overlap with the HOMO of the N-acetyl
tryptophan.[40]

1.3.a Research Conducted
Based on molecular modeling as well as HOMO and LUMO energies, several
chromophores were selected with a variety of ∆ε values (∆ε= |εHOMO,NAcTrp – εLUMO,chromophore|),
high and low, to establish a correlating trend with the modeling and experimental data. The
corresponding Pt(dien) compounds were synthesized (Figure 3.1) and their ability to bind to
tryptophan were evaluated by fluorescence quench experiments. Fluorescence spectroscopy can
be used to monitor small changes occurring on the π-cloud of tryptophan due to π stacking
interactions, and the degree of quenching in the fluorescence spectrum of tryptophan is an
estimate of the strength of the π-π stacking interaction.[45, 46]
The fluorescence data can be used to calculate the association constant, Ka; a
mathematical constant that describes the bonding affinity between two molecules at equilibrium.
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ΔF=-(1/Ka) x (ΔF/Quencher) + ΔFc
ΔF is the difference between fluorescence intensities of N-Acetyl tryptophan with and
without the presence of the platinated nucleobases. ΔFc is the difference when N-Acetyl
tryptophan is completely saturated with the platinated nucleobase. In Figure 1.16 a plot of the
correlation between the frontier orbital data (Figure1.15) and experimental Ka values for 1methylcytosiene (1-MeCyt), 9-ethylguanine (9-EtGua) and their metallated analogues are
shown.[40] The data shows that the ∆ε values for the metal-nucleobase complexes are smaller
for Pt(II) than Pd(II). This data is consistent with fluorescence experiments where a higher Ka
was observed for Pt(II)-nucleobase vs. Pd(II)-nucleobase complexes. Thus, showing that ∆ε
values have an inverse relationship with the experimental Ka values[44]. (Figure 1.16)

Figure 1.16. A plot of the correlation between the frontier orbital data and available
experimental Kπ values for 1-MeCyt, 9-EtGua and their metallated analogues. Points from left to
right correspond to free base, Pd(II)-nucleobase, Pt(II)-nucleobase[40].
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Chapter 2: Platination of Nucleobases
2.1. Abstract
The presence of an aromatic residue(s) such as a tryptophan or phenylalanine provides a
recognition site in which can be selectively targeted by aromatic complexes; opening a plausible
improved or more selective approach to protein-protein or protein-DNA interaction inhibition by
means of non-covalent interactions. Platinated aromatic complexes can further enhance or mimic
the π-π interaction with aromatic residues by decreasing the energy gap between the HOMO of
the π-donor (tryptophan) and the LUMO of the π-acceptor (platinated nucleobase). Fluorescence
spectroscopy can be used to monitor small changes occurring on the π-cloud of tryptophan due to
π stacking interactions, and the degree of quenching in the fluorescence spectrum of tryptophan
is an estimate of the strength of the π-π stacking interaction.[45, 46]
2.2. Introduction
There are several amino acids in the human body that contain aromatic groups and are
capable of π-π stacking interactions. These amino acids play an important role in DNA/RNAprotein recognition; generally involving the amino acids cytosine, guanine, phenylalanine, and
tryptophan.[6, 23, 37, 38] Methylation of purine or pyrimidine based nucleic acids will enhance
the π-π stacking interactions when stacking with tryptophan.[39] This enhancement is due to the
lowering of the energy of the lowest unoccupied molecular orbital (LUMO) of the π acceptor,
bringing it close in energy to the highest occupied molecular orbital (HOMO) of the π donor.
The decrease in the energy gap (ΔE) between the LUMO of the π-acceptor and the HOMO of the
π-donor, improves the acceptor properties toward the π-donor. Coordination of a nucleobase by
either Pt(II) or Pd(II) will produce a complex with a higher net charge (+2), compared to just
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methylation (+1) of the nucleobase; producing a larger decrease in the energy of LUMO by 7-8
eV (electron volts) .[41] Comparing Pt(II) to Pd(II), Pt(II) metallated nucleobases produced a
smaller energy gap between the HOMO of the π-donor (tryptophan) and the LUMO of the πacceptor (metallated nucleobase). This indicates that coordinating a Pt(II) metal to the
nucleobase will enhance the π-stacking interaction versus coordinating a Pd(II) metal.
Most approaches to protein-protein (p53-MDM2) or nucleic acid-zinc finger interaction
(NCp7) inhibition have involved covalent interactions with metallated nucleobases or small
organic molecules. In the case of NCp7 inhibition the approach has involved alkylation or
oxidation of the cysteine residues, which results in a loss of conformation and reducing
infectivity.[47] This approach lacks in the area of selectivity, having little or no DNA selectivity
and therefore causing these complexes to bind/attack in areas other than the desired target. The
presence of an aromatic residue(s) such as a tryptophan or phenylalanine provides a recognition
site in which can be selectively targeted by aromatic complexes; opening a plausible improved or
more selective approach to protein-protein or protein-DNA interaction inhibition by means of
non-covalent interactions. Anzellotti et al has used such an approach by targeting the tryptophan
(W37) of the zinc finger knuckle bound to NCp7.[32] The tryptophan (W37) of the zinc finger
has shown to be inserted between adjacent cytosine and guanine residues and stacking with the
guanine residue. [48] Anzellotti showed by mimicking this interaction by means of small
molecules [Pt(dien)(9-EtGH)]+2 and [Pt(dien)(5’-GMP)] you could stack with the tryptophan
residue (W37); interaction measured by fluorescence spectroscopy. [32] (Figure 2.0)
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Figure 2.0. Noncovalent Interaction of Platinum Complexes with tryptophan and NCp7 (F2)—
Fluorescence.[32]
There was a slight difference between both complexes in stacking with free tryptophan and the
zinc finger but both platinated complexes showed enhanced interaction over the free base
counterpart. [32] Although these platinated bases were successful at mimicking the DNA-protein
stacking interaction and forming an adduct between the zinc finger and the platinated complex;
there was no significant disruption of the three-dimensional structure of the zinc finger.[32]
Though this does provide a new avenue of investigation for selective targeting by means of π-π
stacking interactions.
2.2.a Research Conducted
In this research conducted, several chromophores capable of π-π stacking interactions
were investigated to assess their potential as possible protein-protein or protein-DNA interaction
inhibitors. Based on molecular modeling as well as HOMO and LUMO energies, several
chromophores were selected with a variety of ∆ε values (∆ε= |εHOMO,NAcTrp – εLUMO,chromophore|),
high and low, to establish a correlating trend in stacking capability with the modeling and
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experimental. The corresponding Pt(dien) compounds were synthesized (Figure 2.1) and their
ability to bind to tryptophan were evaluated by fluorescence quench experiments.
2.3 Results and Discussion.
The

systems

examined

were

[Pt(dien)(L)]2+,

where

L=

quinoline

(1),

4-

dimethylaminopyridine (2), benzothiazole (3), 4-methoxypyridine (4), pyridine (5), 4-picoline
(6), thiazole (7), 4-cyanopyridine (8), and 9-ethylguanine (9). (Figure 2.1)

Figure 2.1. Schematic structures of complexes used in this study.
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All complexes were synthesized using [Pt(dien)NO3]NO3 as a starting material. 1H-NMR
spectroscopy of Complex 1 in D20 gave 6 peaks (3.0, 7.6, 7.9, 8.1, 8.3, 8.5, 9.5). The quinoline
protons exhibited a shift upon platination (Δδ≈0.7ppm) in comparison with the free base. (Figure
2.2)

Figure 2.2. 1H-NMR spectroscopy of Complex 1 in D20

1

H-NMR spectroscopy of Complex 2 in D20 gave 3 peaks (δ 3.0, 6.6, 8.0ppm). The 4-

dimehtylaminopyridine protons exhibited only a small shift upon platination (Δδ≈0.1ppm) in
comparison with the free base; probably due to the strong electron donating group of the
dimethylaminogroup donating electron density on to the already electron dense platinum metal
and some of that electron density was donated back onto the nucleobase. (Figure 2.3)
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Figure 2.3. 1H-NMR spectroscopy of Complex 2 in D20

1

H-NMR spectroscopy of Complex 3 in D20 gave 6 peaks (δ 3.0, 7.7, 7.8, 8.1, 8.8, 9.7ppm). The

benzothiazole protons exhibited a shift upon platination (Δδ≈0.5ppm) in comparison with the
free base. (Figure 2.4)
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Figure 2.4. 1H-NMR spectroscopy of Complex 3 in D20
1

H-NMR spectroscopy of Complex 4 in D20 gave 4 peaks (δ 3.0, 3.9, 7.1, 8.4ppm). The pyridine

protons of Complex 4 exhibited a small shift upon platination (Δδ≈0.2ppm) in comparison with
the free base; probably due to the same reason as the 4-dimethylaminopyridine. (Figure 2.5)

Figure 2.5. 1H-NMR spectroscopy of Complex 4 in D20.
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1

H-NMR spectroscopy of Complex 5 in D20 gave 4 peaks (δ 3.0, 7.5, 8.0, 8.7ppm). The pyridine

protons exhibited a shift upon platination (Δδ≈0.7ppm) in comparison with the free base. (Figure
2.6)

Figure 2.6. 1H-NMR spectroscopy of Complex 5 in D20.

1

H-NMR spectroscopy of Complex 6 in D20 gave 4 peaks (δ 2.4, 3.0, 7.38, 8.5ppm). The

pyridine protons of Complex 6 exhibited a shift upon platination (Δδ≈0.2ppm) in comparison
with the free base. (Figure 2.7)

35

Figure 2.7. 1H-NMR spectroscopy of Complex 6 in D20.

1

H-NMR spectroscopy of Complex 7 in D20 gave 4 peaks (δ 3.0, 7.75, 7.94, 9.2ppm). The

thiazole protons exhibited a shift upon platination (Δδ≈0.4ppm) in comparison with the free
base. (Figure 2.8)
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Figure 2.8. 1H-NMR spectroscopy of Complex 7 in D20.

1

H-NMR spectroscopy of Complex 8 in D20 gave 3 peaks (δ 3.0, 7.96, 9.03ppm). The pyridine

protons of Complex 8 exhibited a shift upon platination (Δδ≈0.4ppm) in comparison with the
free base. (Figure 2.9)
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Figure 2.9. 1H-NMR spectroscopy of Complex 8 in D20.

2.4. Stacking Interactions by Fluorescence Spectroscopy:
Fluorescence spectroscopy can be used to monitor small changes occurring on the πcloud of tryptophan due to π stacking interactions, and the degree of quenching in the
fluorescence spectrum of tryptophan is an estimate of the strength of the π-π stacking
interaction.[45, 46] Different π systems, electron donating/electron withdrawing groups, ring
size and extended π systems, were examined to see if the π stacking interaction of the platinated
nucleobase with tryptophan can be enhanced. When examining electron donating groups versus
electron withdrawing groups, pyridine was used as a baseline for comparison with a %
fluorescence quenching of 7.56. (Figure 2.10)

38

a

b

Figure 2.10. (a) absorbance spectrum of Pt(dien)(pyridine)](NO3)2 at 7mM concentration(b)
Fluorescence spectrum of [Pt(dien)(pyridine)](NO3)2 (7mM) stacking with L-acetyl tryptophan
(5µM) after excitation at 280nm. First line is the emission of just tryptophan; last line is
[quencher]/[tryptophan] at 100:10; after ten additions of quencher (7mM)
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It was found that adding strong electron donating/withdrawing groups to the pyridine ring
would increase the π-π stacking interaction with tryptophan. Adding a weak donating group,
CH3, and a moderate donating group, OCH3, only slightly increased the π-π stacking interaction
with tryptophan. [Pt(dien)(4-picoline)]NO3 showed a % fluorescence quenching of 7.96 (Figure
2.11) and [Pt(dien)(4-Methoxypyridine)](NO3) showed a % fluorescence quenching of 8.15.
(Figure 2.12)

a
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b

Figure 2.11. (a) absorbance spectrum of [Pt(dien)(4-picoline)](NO3)2 at 7mM concentration(b)
Fluorescence spectrum of [Pt(dien)(4-picoline)](NO3)2 (7mM) stacking with L-acetyl tryptophan
(5µM) after excitation at 280nm. First line is the emission of just tryptophan; last line is
[quencher]/[tryptophan] at 100:10; after ten additions of quencher (7mM).

a
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b

Figure 2.12. (a) absorbance spectrum of [Pt(dien)(4-methoxypyridine)](NO3)2 at 7mM
concentation(b) Fluorescence spectrum of [Pt(dien)(4-methoxypyridine)](NO3)2 (7mM) stacking
with L-acetyl tryptophan(5µM) after excitation at 280nm. First line is the emission of just
tryptophan; last line is [quencher]/[tryptophan] at 100:10; after ten additions of quencher (7mM).

The addition of a strong electron donating group, dimethylamino, to the pyridine ring
greatly enhanced the π-π stacking interaction with tryptophan. [Pt(dien)(4Dimethylaminopyridine)](NO3) showed a % fluorescence quenching of 65.4. (Figure 2.13)
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a

b

Figure 2.13. (a) absorbance spectrum of Pt(dien)(4-Dimethylaminopyridine)](NO3)2 at 7mM
concentration (b)Fluorescence spectrum of Pt(dien)(4-Dimethylaminopyridine)](NO3)2 (7mM)
stacking with L-acetyl tryptophan (5µM) after excitation at 280nm. First line is the emission of
just tryptophan; last line is [quencher]/[tryptophan] at 100:10; after ten additions of quencher
(7mM)
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The addition of a strong electron withdrawing group, cyano, to the pyridine ring greatly
enhanced the π-π stacking interaction with tryptophan as well. [Pt(dien)(4-cyanopyridine)](NO3)
showed a % fluorescence quenching of 63.45. (Figure 2.14)
a

b
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Figure 2.14. (a) absorbance spectrum of Pt(dien)(4-cyanopyridine)](NO3)2 at 7mM
concentration (b) Fluorescence spectrum of Pt(dien)(4-cyanopyridine)](NO3)2 (7mM) stacking
with L-acetyl tryptophan (5µM) after excitation at 280nm. First line is the emission of just
tryptophan; last line is [quencher]/[tryptophan] at 100:10; after ten additions of quencher (7mM).
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The size of the ring also has an effect on the stacking capability. Comparing the 6 member ring
pyridine versus 5 member ring thiazole it was found that the 6 member ring size has more of an
effect than originally expected. [Pt(dien)(pyridine)]NO3 has shown a % fluorescence quenching
of 7.56, [Pt(dien)(thiazole)]NO3 showed a minimal % fluorescence quenching of 4.32. (Figure
2.15)

a
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b

Figure 2.15. (a) absorbance spectrum of [Pt(dien)(thiazole)](NO3)2 at 7mM concentration
(b)Fluorescence spectrum of [Pt(dien)(thiazole)](NO3)2 (7mM) stacking with L-acetyl
tryptophan(5µM) after excitation at 280nm. First line is the emission of just tryptophan; last line
is [quencher]/[tryptophan] at 100:10; after ten additions of quencher (7mM).

Extending these two π systems further improved the stacking with tryptophan. The two
compounds examined were benzothiazole and quinoline, just an addition of benzene to the
previous two compounds. [Pt(dien)(benzothiazole)](NO3) showed a % fluorescence quenching of
36.24 (figure 2.16) and [Pt(dien)(quinoline)](NO3) showed a % fluorescence quenching of 29.41.
(Figure 2.17)
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b

Figure 2.16. (a) absorbance spectrum of Pt(dien)(benzothiazole)](NO3)2 at 7mM concentration
(b)Fluorescence spectrum of [Pt(dien)(benzothiazole)](NO3)2 (7mM) stacking with L-acetyl
tryptophan (5µM) after excitation at 280nm. First line is the emission of just tryptophan; last line
is [quencher]/[tryptophan] at 100:10; after ten additions of quencher (7mM).
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a

b

Figure 2.17. (a) absorbance spectrum of [Pt(dien)(quinoline)](NO3)2 at 7mM
concentration(b)Fluorescence spectrum of [Pt(dien)(quinoline)](NO3)2 (7mM) stacking with Lacetyl tryptophan (5µM) after excitation at 280nm. First line is the emission of just tryptophan;
last line is [quencher]/[tryptophan] at 100:10; after ten additions of quencher (7mM).
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2.5. Experimental Section
Materials. Quinoline, 4-Dimethylaminopyridine, Benzothiazole, 4-Methoxypyridine, Pyridine,
4-Picoline, Thiazole, 4-Cyanopyridine, 9-Ethylguanine and N-Acetyltrypotophan were Alfa
Aesar, Sigma Aldrich and TCI America; complex [Pt(dien)(NO3)](NO3)

was synthesized

according to reported procedures.[49]
Nuclear Magnetic Resonance experiments. 1H NMR spectra were recorded on a Varian
Mercury series 300 MHz Spectrometer using a 5-mm tube; chemical shifts were referenced to a
residual signal in D2O (4.79ppm) and DMF-d7 (8.00 ppm).

195

Pt-NMR were recorded on a

Varian Mercury series 300 MHz Spectrometer using a 10-mm tube. Chemical shifts were
referenced to K2[PtCl6]. The scanning frequency for 195Pt nuclei was set at 64.32 MHz.
Fluorescence Experiments. In a typical experiment, 3 mL of N-AcTrp (5 µM) were titrated
with aliquots of the corresponding quenching compound (7 mM) with a ratio of ([quencher]/[NAcTrp]) 100-10; 10.5 mM Phosphate buffer adjusted with a few drops of HCL was used in all
experiments (pH 7.0). The maximum intensity of the spectrum (ca. 357 nm) was measured for
each addition, and the association constants for each system were obtained from the analysis of
the Eadie-Hofstee plots.[50] Measurements were made at 20°C, and the reported % fluorescence
quenching of tryptophan were averaged over a number of three different experiments.
Fluorescence spectra were recorded in the range of 320-420 nm with a scan rate of 120nm/min.

49

2.5.1. Synthesis and Characterization of complexes.
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Pt(Cl2)(DMSO2). Pt(Cl2)(DMSO2) prepared similar to a reported procedure.[51] K2PtCl4 was
suspended in 10 mL H2O and reacted with a 1:1 molar ratio of DMSO at room temperature for
24 hrs. Precipitate was filtered and washed with water, ethanol, and ether and dried in vacuo
(84% yield).1H-NMR (D2O) δ 3.65.

[Pt(dien)Cl]Cl. [Pt(dien)Cl]Cl was prepared similar to a reported procedure.[52] PtCl2DMSO2
was suspended in 120 mL methanol and reacted with a 1:1 molar ratio of diethyltriamine at
reflux for 4 hrs. Solution was evaporated down to ~10 mL and 5ml of methanol was added. After
this ether was added and white solid appeared. Centrifuge was used to obtain the solid. Solid was
then dried in vacuo (86% yield). 1H-NMR (D2O) δ 2.8.

[Pt(dien)(Quinoline)](NO3)(1). [Pt(dien)(Quinoline)](NO3) was prepared similar to a reported
procedure.[53] Two equivalents of AgNO3 were added to a solution of [Pt(dien)Cl]Cl in H2O
and solution stirred overnight to remove the chloride ligands and produce the complex
[Pt(dien)NO3]NO3 in situ. The solution was then filtered and lyophilized to produce a white
solid. The white solid was dissolved in DMF and Quinoline was then added in 3-1 molar
amounts and the mixture was stirred overnight. Solution was evaporated down to ~5 mL and 5
mL of methanol was added and an off white solid was obtained upon addition of ether and
centrifugation. Solid dried in vacuo (50% yield). 1H-NMR (D2O) δ 3.0, 7.6, 7.9, 8.1, 8.3, 8.5,
9.5. . Calcd for C13H20N6O6Pt: C, 28.32; H, 3.66 ; N, 15.24. Found: C 27.76; H, 3.45; N, 14.88%.
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[Pt(dien)(4-Dimethylaminopyridine)](NO3)(2).

[Pt(dien)(4-Dimethylaminopyridine)](NO3)

was prepared similar to that of [Pt(dien)(Quinoline)](NO3) using 4-Dimethylaminopyridine as
the nucleobase and H2O as the solvent (26% yield). 1H-NMR (D2O) δ 3.0, 6.6, 8.0. Calcd for
C11H23N7O6Pt: C, 24.27; H, 4.26; N, 18.01. Found: C, 23.91; H, 4.89; N,19.62 %.

[Pt(dien)(Benzothiazole)](NO3)(3). [Pt(dien)(Benzothiazole)](NO3) was prepared similar to that
of [Pt(dien)(4-Dimethylaminopyridine)](NO3) using benzothiazole as the nucleobase (29%
yield). 1H-NMR (D2O) δ 3.0, 7.7, 7.8, 8.1, 8.8, 9.7. Calcd for C11H18N6O6Pt: C, 23.70; H, 3.25;
N, 15.08. Found: C, 23.14; H, 3.29; N, 14.26 %.

[Pt(dien)(4-Methoxypyridine)](NO3)(4). [Pt(dien)(4-Methoxypyridine)](NO3) was prepared
similar to that of [Pt(dien)(4-Dimethylaminopyridine)](NO3) using 4-mehtoxypyridine as the
nucleobase (24% yield). 1H-NMR (D2O) δ 3.0, 3.9, 7.1, 8.4. Calcd for C10H20N6O7Pt: C, 22.60;
H, 3.79; N, 15.82. Found: C, 21.31; H, 3.91; N, 15.41 %.

[Pt(dien)(pyridine)](NO3)(5). [Pt(dien)(pyridine)](NO3) was prepared similar to that of
[Pt(dien)(4-Dimethylaminopyridine)](NO3) using pyridine as the nucleobase (62% yield). 1HNMR (D2O) δ 3.0, 7.5, 8.0, 8.7. Calcd for C9H18N6O6Pt: C, 21.56; H, 3.62; N, 16.76. Found: C
21.28; H, 3.34; N, 15.86%.

[Pt(dien)(4-picoline)](NO3)(6). [Pt(dien)(4-picoline)](NO3) was prepared similar to that of
[Pt(dien)(4-Dimethylaminopyridine)](NO3) using 4-picoline as the nucleobase (48% yield). 1H-
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NMR (D2O) δ 2.4, 3.0, 7.38, 8.5. Calcd for C10H20N6O6Pt: C, 23.30; H, 3.91; N, 16.31. Found:
C, 22.82; H, 3.69; N, 15.39%.

[Pt(dien)(Thiazole)](NO3)(7). [Pt(dien)(Thiazole)](NO3) was prepared similar to that of
[Pt(dien)(4-Dimehtylaminopyridine)](NO3) using thiazole as the nucleobase (39% yield). 1HNMR (D2O) δ 3.0, 7.75, 7.94, 9.2. Calcd for C7H16N6O6PtS: C, 16.57; H, 3.18; N, 16.56. Found:
C, 16.74; H, 2.67; N, 16.07%.

[Pt(dien)(4-Cyanopyridine)](NO3)(8). [Pt(dien)(4-Cyanopyridine)](NO3) similar to that of
[Pt(dien)(4-Dimethylaminopyridine)](NO3) using 4-cyanopyridine as the nucleobase and heating
at 40°C (23% yield). 1H-NMR (D2O) δ 3.0, 7.94, 9.0. Calcd for C10H17N7O6Pt: C, 22.82; H, 3.26;
N, 18.63. Found: C, 21.93; H, 3.19; N, 18.11%.

[Pt(dien)(9-Ethylguanine)](NO3)(9) was a gift from Dr. Q.A. dePaula.

Table 1. Pt(dien)L data.
L
Benzothiazole
4-Cyanopyridine
4-Dimethylaminopyridine
4-Methoxypyridine
4-Picoline
Quinoline
Pyridine
Thiazole

δ195Pt
(ppm)
-2861
-2839
-2816
-2824
-2835
-2837
-2833
-2820

λmax
(nm)
262.5
274
277.5
257
257.5
305.5
257.5
258.5

pKa’s of L

ɛ @ λmax

ɛ @ λmeasured

1.2
1.92
9.2
6.56
6.25
4.85
5.14
2.44

2625000
2740000
2775000
2570000
2575000
3055000
2575000
2585000

3570000
3570000
3570000
3570000
3570000
3570000
3570000
3570000
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Table 2. 195Pt coupling (J) values (Hz)
L
Benzothiazole
4-Cyanopyridine
4-Dimethylaminopyridine
4-Methoxypyridine
4-Picoline
Quinoline
Pyridine
Thiazole

195

Pt coupling ( 3J (Pt-H)) value (Hz)
48.568
55.715
52.391
55.368
56.154
101.883
58.424
44.959

2.6. Conclusion
Trends have been established when examining the stacking capability of platinum(II)
complexes with tryptophan (figure 2.17); adding a strong electron donating/withdrawing group
or extending the π system of pyridine can significantly enhance the π-π stacking interaction with
tryptophan. This can be useful in being applied to recognition processes of proteins or
DNA/RNA that contain tryptophan.
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Figure 2.18. % fluorescence quenching of tryptophan by [Pt(dien)nucleobase]NO3
complexes.
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Supplemental Information.
Table 1. Pt(dien)L data.
L
Benzothiazole
4-Cyanopyridine
4-Dimethylaminopyridine
4-Methoxypyridine
4-Picoline
Quinoline
Pyridine
Thiazole

δ195Pt
(ppm)
-2861
-2839
-2816
-2824
-2835
-2837
-2833
-2820

λmax
(nm)
262.5
274
277.5
257
257.5
305.5
257.5
258.5

pKa’s of L

ɛ @ λmax

ɛ @ λmeasured

1.2
1.92
9.2
6.56
6.25
4.85
5.14
2.44

2625000
2740000
2775000
2570000
2575000
3055000
2575000
2585000

3570000
3570000
3570000
3570000
3570000
3570000
3570000
3570000

Table 2. 195Pt coupling (J) values (Hz)
L
Benzothiazole
4-Cyanopyridine
4-Dimethylaminopyridine
4-Methoxypyridine
4-Picoline
Quinoline
Pyridine
Thiazole

195

Pt coupling ( 3J (Pt-H)) value (Hz)
48.568
55.715
52.391
55.368
56.154
101.883
58.424
44.959

